Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: Susceptibility and clinical outcome

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 4, 2013, Pages 315-319

  Kim, Nak Hyun ^a   Hwang, Jeong Hwan ^a   Song, Kyoung Ho ^a   Choe, Pyoeng Gyun ^a   Kim, Eu Suk ^a   Park, Sang Won ^a   Kim, Hong Bin ^a   Kim, Nam Joong ^a   Park, Wan Beom ^a   Oh, Myoung Don ^a  

^a Seoul National University   (South Korea)

Author keywords

Acinetobacter baumannii; Bacteraemia; Carbapenem resistance; Tigecycline

Indexed keywords

AMIKACIN; CARBAPENEM; COLISTIN; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA; CATHETER INFECTION; CLINICAL ARTICLE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME;

EID: 84875452338     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.732705     Document Type: Article

References (26)

1. Maragakis LL, Perl T M. A cinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008 ; 46 : 1254-63.
2. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009 ; 63 : 775-80.
3. Poulakou G, Kontopidou F V, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J Infection 2009 ; 58 : 273-84.
4. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, et al. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008 ; 62(Suppl 1) : i29-40.
5. Vila J, Pachon J. T herapeutic options for Acinetobacter baumannii infections. Expert Opin Pharmacother 2008 ; 9 : 587-99.
6. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008 ; 46 : 567-70.
7. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010 ; 10 : 287.
8. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, et al. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 2008 ; 61 : 729-33.
9. Schafer JJ, Goff DA, Stevenson KB, Mangino J E. E arly experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007 ; 27 : 980-7.
10. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientifi c evidence. J Antimicrob Chemother 2008 ; 62 : 45-55.
11. Peleg A Y, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007 ; 59 : 128-31.
12. Kuo S C, Wang F D, Fung C P, Chen L Y, Chen S J, Chiang MC, et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect 2011 ; 44 : 45-51.
13. Knaus WA,D raper E A, Wagner D P, Zimmerman J E. APACHE II: a severity of disease classifi cation system. Crit Care Med 1985 ; 13 : 818-29.
14. Rhee J Y, Kwon K T, Ki H K, Shin S Y, Jung D S, Chung D R, et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the Acute Physiology and Chronic Health Evaluation II scoring systems. Shock 2009 ; 31 : 146-50.
15. Wyeth. T YGACIL (tigecycline) FOR INJECTION for intravenous use. Philadelphia, PA: Wyeth Pharmaceuticals Inc .; 2011.
16. Clinical and Laboratory Standards Institute. M ethods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, eighth edition. M07-A8. Wayne, PA: CLSI ; 2009.
17. Clinical and Laboratory Standards Institute. P erformance standards for antimicrobial susceptibility testing; twentieth informational supplement. M100-S20. Wayne, PA: CLSI ; 2010.
18. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website (EUCAST version 5.13). EUCAST ; 2012.
19. Navon-Venezia S, Leavitt A, Carmeli Y. H igh tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007 ; 59 : 772-4.
20. Meagher A K, Ambrose PG, Grasela T H, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profi le of tigecycline. Clin Infect Dis 2005 ; 41(Suppl 5) : S333-40.
21. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005 ; 49 : 220-9.
22. Cisneros JM, Rodriguez-Bano J. N osocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 2002 ; 8 : 687-93.
23. Kumar A, Roberts D, Wood K E, Light B, Parrillo J E, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006 ; 34 : 1589-96.
24. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 ; 36 : 296-327.
25. Freire A T, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010 ; 68 : 140-51.
26. Jean SS, Hsueh PR. C urrent review of antimicrobial treatment of nosocomial pneumonia caused by multidrug-resistant pathogens. Expert Opin Pharmacother 2011 ; 12 : 2145-8.